Source

Nature Medicine

3 developments in the corpus

Latest

Everything in the corpus, newest first.

OCT 23, 2026 · JOURNAL ARTICLE

Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial

Nature Medicine

Camupepimut (ELI-002 7P) drives mutated KRAS (mKRAS)-specific T cell responses that correlated with disease-free survival (DFS) and overall survival (OS) in patients with mKRAS pan

SEP 22, 2026 · JOURNAL ARTICLE

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial

Nature Medicine

Biliary tract cancers (BTCs) are associated with poor outcomes despite recent incorporation of immune checkpoint inhibitors into first-line chemotherapy. Human epidermal growth fac

AUG 11, 2026 · JOURNAL ARTICLE

Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancer

Nature Medicine

Mechanistic analysis of acquired resistance in a Phase 1/2 trial, identifying actionable pathways and guiding rational combination strategies, but requiring confirmatory evidence from the ongoing Phase 3 trial.

PromisingSumit Kar Ida Aronchik Lung Cancer Treatments and Mutations

Reported

Patients with RAS pathway alterat…26 of 44 (59%)

Patients with mutant KRAS amplifi…16 of 44 (36%)

Patients with RTK pathway alterat…4 of 44 (9%)